Products

A new pharmaceutical product based upon vanadium and Aonys, NP01 improves insulin sensitivity leading to insulin-sensitisation of peripheral tissues.

A new pharmaceutical product based upon lithium and Aonys, NP03 has been shown to have a neuroprotector role which could have uses in a number of neurodegerative diseases.

A new pharmaceutical product based upon lithium and Aonys, NP07 is a potent mood stabiliser for the treatment of bipolar disporder.  Current "gold standard" lithium treatment for bipolar disorder requires constant patient monitoring to achieve the balance between therapeutic and undesirable effects.  Due to difficulties in maintaining this balance, a significant number of patients are unable to maintain satisfactory mood stabilisation.

The field of RNA interference represents a potential revolution in medicine and a new approach to treating disease.